Clinical trial · no report yet · Phase 3
IRAKLIA
SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM
- NCT05405166 ↗
- Active not recruiting
- Sanofi
- 59 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 29 | |
| X threads | 18 | |
| Podcasts | 12 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Phase 3, Open Label Study Evaluating Subcutaneous Versus Intravenous Administration of Isatuximab in Combination With Pomalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Plasma Cell Myeloma Recurrent
- Interventions
- Isatuximab IV; Isatuximab SC; Dexamethasone; Pomalidomide; Dexamethasone; Montelukast; Paracetamol / Acetaminophen; Diphenhydramine; Methylprednisolone
- Arms
- Isatuximab Subcutaneous (SC) · Experimental
- Isatuximab Intravenous (IV) · Active comparator
- Enrollment
- 531
- Primary outcomes
- Overall Response Rate (ORR)
- Observed Concentration Before Dosing (Ctrough) of Isatuximab at Steady State
- Sponsor
- Sanofi
- Start
- Jun 23, 2022
- Primary completion
- Nov 6, 2024
- Results posted
- Yes
- Registry record
- NCT05405166 · updated Sep 2, 2026
Publications
linked from the registry- Ailawadhi S, Spicka I, Spencer A, Lu J, Oriol A, Ling S, Schjesvold F, Berkovits A, Hus M, Li C, Dimopoulos MA, Rajnics P, Besisik SK, Hungria V, Custidiano MDR, Parmar G, Leleu X, Li F, Cerchione C, Gomez C, Ishida T, Mateos MV, Buck TT, LeBlanc R, Minarik J, Goldschmidt H, Zhang R, Semiond D, Suzan F, Stefanova-Urena M, Koch V, Moreau P. Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study. J Clin Oncol. 2025 Aug;43(22):2527-2537. doi: 10.1200/JCO-25-00744. Epub 2025 Jun 3. PubMed 40459178